---
title: "Bilcare Ltd (526853) — Share Price, Financials & Analysis"
symbol: "526853"
company: "Bilcare Ltd"
canonical: "https://tapetide.com/stocks/526853"
isin: "INE986A01012"
nse_symbol: "BI"
bse_code: "526853"
sector: "Healthcare"
industry: "Healthcare Technology"
market_cap_cr: 211.91
generated_at: "2026-09-13T18:59:35.587Z"
---

# Bilcare Ltd (526853)

Canonical page: https://tapetide.com/stocks/526853

## Company

- **NSE Symbol:** BI
- **BSE Code:** 526853
- **ISIN:** INE986A01012
- **Sector:** Healthcare
- **Industry:** Healthcare Technology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2026-04-20
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** bilcare-group.com

## About

Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).

## Latest Price

- **Price:** ₹92.92
- **Change:** +3.09 (+3.44%)
- **Open:** ₹89.99
- **Day High:** ₹93.6
- **Day Low:** ₹87.75
- **Previous Close:** ₹89.83
- **Volume:** 31238
- **As Of:** 2026-09-11T10:20:09+00:00

## Key Fundamentals

Observed at 2026-09-11T04:49:59.977665Z.

- **Market Cap:** ₹211.91 Cr
- **Classification:** Microcap
- **P/E (reported):** -33.1
- **P/E (TTM):** 14.91
- **EPS (TTM):** ₹6.23
- **Book Value:** ₹83.55
- **Price to Book:** 1.07
- **Dividend Yield:** 0%
- **ROE:** -9.53%
- **ROCE:** 1.03%
- **Debt to Equity:** 3.15
- **Revenue (yearly):** ₹733.54 Cr
- **Net Income:** ₹-21.41 Cr
- **EBITDA:** ₹40.63 Cr
- **52-Week High:** ₹111.51
- **52-Week Low:** ₹51.62
- **RSI (14):** 54.93

## Tapetide Score

- **Score:** 52 / 100
- **Score date:** 2026-09-04
- **Archetype:** Average Quality, Undemanding Price
- **What it means:** The financials sit mid-range rather than strong, and the multiple is not demanding. Nothing here stands out in either direction, so the read comes down to which single pillar you weight most and whether the next results move it off the middle.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Rising
- **Percentile:** 56.6 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 20.72 | 9% |
| growth | 35.55 | 9% |
| momentum | 98.31 | 12% |
| ownership | 50 | 24% |
| quality | 53 | 22% |
| valuation | 71.32 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 1.11 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 3.33% over past five years.
- Promoter holding is low: 30.0%
- Company has a low return on equity of -4.07% over last 3 years.
- Contingent liabilities of Rs.727 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 994.84% | 51.34% | -75.62% |
| ebitda margin growth | 25.85% | -31.97% | -33.58% | -39.06% |
| net income growth | 92.31% | -61.9% | 37% | 16% |
| revenue growth | 12.62% | -9.05% | -9% | 3% |
| roce | 33.77% | 24.1% | -94.95% | 7.59% |
| roe | 90.7% | 5.19% | -3.82% | 40.15% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 190 | 175 | 200 | 194 | 202 | 198 | 194 | 186 | 178 | 181 | 188 | 226 |
| Expenses | 173 | 158 | 208 | 175 | 194 | 187 | 186 | 175 | 175 | 168 | 171 | 189 |
| Operating Profit | 17 | 17 | -8 | 19 | 8 | 11 | 8 | 11 | 3 | 13 | 17 | 37 |
| OPM % | 9 | 10 | -4.1 | 10 | 3.8 | 5 | 4 | 6 | 1.9 | 7 | 9 | 16 |
| Other Income | 1 | 4 | 9 | 4 | -6 | -6 | 21 | 6 | 4 | 3 | 12 | 0 |
| Interest | 20 | 21 | 23 | 21 | 24 | 19 | 19 | 19 | 19 | 17 | 18 | 18 |
| Depreciation | 10 | 11 | 13 | 12 | 11 | 12 | 5 | 12 | 12 | 5 | 5 | 4 |
| Profit before tax | -13 | -10 | -35 | -10 | -33 | -27 | 6 | -13 | -24 | -6 | 7 | 15 |
| Tax % | -5 | 34 | -44 | 55 | -10 | -40 | -119 | -25 | -1 | 3 | -13 | -1 |
| Net Profit | -12 | -14 | -20 | -15 | -30 | -16 | 12 | -10 | -23 | -6 | 8 | 15 |
| EPS in Rs | -3.22 | -2.91 | -4.63 | -2.71 | -6.81 | -3.04 | 7.47 | -1.61 | -5.25 | 0.41 | 5.68 | 5.39 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2778 | 2997 | 1827 | 623 | 845 | 982 | 747 | 788 | 734 | 773 |
| Expenses | 2617 | 2827 | 1782 | 572 | 784 | 925 | 708 | 743 | 689 | 703 |
| Operating Profit | 161 | 170 | 45 | 51 | 60 | 57 | 39 | 45 | 44 | 70 |
| OPM % | 6 | 6 | 2.5 | 8 | 7 | 6 | 5 | 6 | 6 | 9 |
| Other Income | 297 | 59 | 254 | 45 | 44 | 237 | 16 | 12 | 26 | 20 |
| Interest | 249 | 283 | 174 | 76 | 69 | 60 | 82 | 82 | 72 | 72 |
| Depreciation | 416 | 378 | 239 | 46 | 39 | 38 | 45 | 46 | 20 | 26 |
| Profit before tax | -207 | -433 | -114 | -25 | -4 | 196 | -72 | -71 | -21 | -7 |
| Tax % | -4 | 5 | -13 | -55 | 3 | 74 | -18 | -21 | -19 | — |
| Net Profit | -199 | -453 | -99 | -11 | -4 | 50 | -59 | -56 | -17 | -6 |
| EPS in Rs | -85.43 | -193.28 | -43.97 | -8.95 | -5.35 | 6.39 | -14.12 | -12.23 | 0.73 | 6.23 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 590 | 376 | -93 | 85 | 63 | 52 | 507 | 474 | 445 | 173 |
| Borrowings | 2014 | 2089 | 2270 | 707 | 677 | 690 | 639 | 756 | 682 | 620 |
| Other Liabilities | 830 | 913 | 888 | 297 | 300 | 362 | 424 | 314 | 266 | 26 |
| Total Liabilities | 3457 | 3402 | 3087 | 1112 | 1064 | 1127 | 1593 | 1568 | 1417 | 843 |
| Fixed Assets | 2403 | 2180 | 2005 | 534 | 494 | 465 | 1045 | 1038 | 949 | 433 |
| CWIP | 149 | 170 | 79 | 0 | 0 | 1 | 1 | 1 | 4 | 8 |
| Investments | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 8 | 11 | 14 |
| Other Assets | 904 | 1051 | 1003 | 577 | 570 | 661 | 545 | 521 | 453 | 387 |
| Total Assets | 3457 | 3402 | 3087 | 1112 | 1064 | 1127 | 1593 | 1568 | 1417 | 843 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 300 | 98 | 206 | 256 | 72 | 41 | -7 | 62 | 85 | 128 |
| Cash from Investing Activity | -129 | -203 | -104 | 1309 | 2 | -4 | 36 | -106 | 81 | -6 |
| Cash from Financing Activity | -155 | 91 | -103 | -1600 | -83 | -55 | -19 | 36 | -169 | -132 |
| Net Cash Flow | 16 | -13 | -1 | -35 | -9 | -18 | 10 | -7 | -3 | -10 |
| Free Cash Flow | 165 | -115 | 91 | 1569 | 69 | 37 | 11 | -34 | 140 | 120 |
| CFO/OP | 173 | 75 | 148 | 828 | 141 | 78 | -6 | 162 | 193 | 284 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 29 | 38 | 38 | 22 | 90 | 95 | 70 | 73 | 55 | 54 |
| Inventory Days | 84 | 90 | 82 | 28 | 90 | 83 | 42 | 77 | 80 | 86 |
| Days Payable | 81 | 102 | 71 | 35 | 93 | 102 | 77 | 70 | 57 | 70 |
| Cash Conversion Cycle | 32 | 25 | 49 | 15 | 88 | 76 | 34 | 80 | 78 | 69 |
| Working Capital Days | -11 | -150 | -156 | -2 | -19 | -10 | -10 | 12 | -5 | 28 |
| ROCE % | 2 | -8 | -6 | -9 | 3 | 3 | 3 | 1 | 1 | 6 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% |
| FIIs | 0.04% | 0% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 46.1% | 45.91% | 45.48% | 45.57% | 45.51% | 45.4% | 44.68% | 44.96% | 45.4% | 45.45% | 45.18% | 45.32% |
| Others | 23.84% | 24.08% | 24.46% | 24.37% | 24.43% | 24.55% | 25.26% | 24.99% | 24.54% | 24.49% | 24.76% | 24.62% |
| No. of Shareholders | 19875 | 19181 | 19116 | 18783 | 18241 | 18496 | 17586 | 17047 | 16513 | 16068 | 15824 | 15777 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 5 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 92.34 | Buy |
| EMA (10) | 92.29 | Buy |
| SMA (20) | 92.99 | Sell |
| EMA (20) | 88.79 | Buy |
| SMA (50) | 74.53 | Buy |
| EMA (50) | 79.02 | Buy |
| SMA (100) | 68.21 | Buy |
| EMA (100) | 72.78 | Buy |
| SMA (200) | 68.15 | Buy |
| EMA (200) | 70.6 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 57.79 | Neutral |
| MACD (12,26,9) | 5.43 | Sell |
| Stochastic (14,3,3) | 32.51 | Neutral |
| ADX (14) | 34.98 | Buy |
| Williams %R (14) | -60.2 | Neutral |
| ATR (14) | 5.88 | High Volatility |
| ROC (12) | 0.92 | Buy |
| Stoch RSI (14) | 18.69 | Buy |
| UO (7,14,28) | 54.03 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45497308-0699-44a2-9592-edccb3b5b0d0.pdf) |
| 2026-09-04 | [Annual Report - 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec951fe9-0d83-446c-a00b-5c8c914016fd.pdf) |
| 2026-09-04 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bac2be54-66de-4305-8583-7e4f4d4474b0.pdf) |
| 2026-09-04 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7390bbfe-6f3b-40db-930c-6163ed14d695.pdf) |
| 2026-08-22 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4B185696_D7EE_4F62_8CE5_51898707F35D_103832.pdf) |
| 2026-08-15 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f477188-814a-41c6-ae16-d05e067f45b5.pdf) |
| 2026-08-13 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9b4a02b-5388-45f6-8c91-170f61841aec.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27121ea6-b55a-4815-9de1-3da2fcbc3f99.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fcb5eab5-f24c-4dcb-82fa-b7e7d7324bd2.pdf) |
| 2026-08-13 | [Appointment of Company Secretary and Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89a9e4b7-bc0f-4363-8a74-43ead8c00a5f.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Standalone & Consolidated Unaudited Financial Results For The Quarter Ended On 30 June 2026 Along With Limited Review Report Issued By Statutory Auditors Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f8b527a-d962-442a-9e6d-6632a1e8fcfc.pdf) |
| 2026-05-30 | [Audited Financial Results For The Quarter And Period Ended On 31 March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a65ce998-4421-489b-b9d7-327cf716c71c.pdf) |
| 2026-02-12 | [Unaudited Financials Result (Standalone And Consolidated) For The Quarter And Nine Months Ended 31.12.2025 Along With Limited Review Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bfeaaec-5f19-47dd-900d-11856a7a2fdc.pdf) |
| 2025-11-14 | [Unaudited Financials Result (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2025 Along With Limited Review Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93f1103e-ad08-4545-9aff-2a978b0a9e24.pdf) |
| 2025-08-14 | [Unaudited Financials Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2025 Together With The Limited Review Report Of The Statutory Auditors Thereon.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=608d28c6-7043-472a-abec-0b3e071e9966.pdf) |
| 2025-05-29 | [Submission Of Audited Financial Results Under Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter And Year Ended 31 March 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=456e6518-1dee-442d-9209-2ca3be25a636.pdf) |
| 2025-02-13 | [Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Nine Months Ended 31St December 2024 Together With The Limited Review Report Of The Statutory Auditors Thereon.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27a34eb4-2eae-4797-88df-54826b8a604c.pdf) |
| 2025-02-13 | [Unaudited Financials Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2024 Together With The Limited Review Report Of The Statutory Auditors Thereon.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=990de9fa-83b6-4e00-8778-b9d69201e8d3.pdf) |
| 2024-11-13 | [Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d297e1dc-d04e-493e-bd73-c803a628f800.pdf) |
| 2024-08-14 | [Unaudited Financials Result (Standalone And Consolidated) For The Quarter Ended 30.06.2024 Along With Limited Review Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af5f1829-a93c-4ba4-beee-4c4e918305f3.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 6h - Maharashtra GST inspection/search concluded 16 Feb 2026; company provided documents, no official findings or material impact. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 6h - Maharashtra GST inspection/search concluded 16 Feb 2026; company provided documents, no official findings or material impact.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e937f01c-543e-4e07-8b63-3c79ad4d1e24.pdf) |
| 5 Feb - Q3 FY26 consolidated revenue Rs.465cr, PAT Rs.28cr; 9M revenue Rs.1,586cr; FDA approves pilocarpine ophthalmic solutions. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Feb - Q3 FY26 consolidated revenue Rs.465cr, PAT Rs.28cr; 9M revenue Rs.1,586cr; FDA approves pilocarpine ophthalmic solutions.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7be17a35-6137-422d-a21b-8790dc3ee7aa.pdf) |
| 4h - Adv. Ashwini Hasabnis appointed additional independent director from 25 Apr 2026; committees reconstituted. | [Announcement under Regulation 30 (LODR)-Change in Directorate 4h - Adv. Ashwini Hasabnis appointed additional independent director from 25 Apr 2026; committees reconstituted.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ff7561fa-3b31-45c9-8e82-b8a41aba3614.pdf) |
| 3h - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted. | [Announcement under Regulation 30 (LODR)-Cessation 3h - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e9bc5ed4-ef38-4314-9b06-64a238451855.pdf) |
| 30 Mar - Redeemed ₹3.15 crore pref shares; converted 12.9L warrants to equity; Caprihans stake now 59.56%; UK subsidiary liquidated. | [Announcement Under Regulation 30 30 Mar - Redeemed ₹3.15 crore pref shares; converted 12.9L warrants to equity; Caprihans stake now 59.56%; UK subsidiary liquidated.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57c60e4d-63a0-4010-adef-3bce35b3a207.pdf) |
| 30 Mar - Converted 12,90,000 warrants to equity (Mar 20–25, 2026); redeemed 31,50,000 prefs ₹3.15 crore; UK subsidiary liquidated. | [Board Meeting Outcome for Outcome Of Board Meeting 30 Mar - Converted 12,90,000 warrants to equity (Mar 20–25, 2026); redeemed 31,50,000 prefs ₹3.15 crore; UK subsidiary liquidated.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/207091e2-c564-4d53-8ae8-225be05739e3.pdf) |
| 30 Mar - Converted 12,90,000 warrants into shares; redeemed 31,50,000 prefs (₹3.15cr); Bilcare GCS liquidation completed. | [Update On Voluntary Liquidation Of Wholly Owned Subsidiary - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015, 30 Mar - Converted 12,90,000 warrants into shares; redeemed 31,50,000 prefs (₹3.15cr); Bilcare GCS liquidation completed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7facfb41-db70-4b33-961a-d9f9d665a25a.pdf) |
| 29 Apr - Bilcare confirms it is not a Large Corporate under SEBI debt fundraising circular. | [Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/ CIR/2023/172 Dated October 19, 2023 29 Apr - Bilcare confirms it is not a Large Corporate under SEBI debt fundraising circular.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d2390d1-1c4a-4af2-8b12-a12020928753.pdf) |
| 29 Apr - Bilcare confirms it is not a Large Corporate under SEBI debt fundraising circular. | [Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/ CIR/2023/172 Dated October 19, 2023 29 Apr - Bilcare confirms it is not a Large Corporate under SEBI debt fundraising circular.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4d2390d1-1c4a-4af2-8b12-a12020928753.pdf) |
| 25 Apr - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted. | [Announcement under Regulation 30 (LODR)-Cessation 25 Apr - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9bc5ed4-ef38-4314-9b06-64a238451855.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_FDC_2011_2012_11072012121551.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f883777c-ea48-419a-ae7f-8fa56e77856a.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/da58eef9-a234-4d68-9a84-b79d86378cfc.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/44e9e558-8f82-4929-acbd-3f27f2f1fb69.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/999f29ad-b578-4b9e-9935-08a5cb417f35.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/af599cac-85c4-49d9-8e82-a7b47c5a67e9.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/06aa5506-71e8-44fe-8bd5-ce9920df3573.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/531599/74935531599.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/526853/73586526853.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/531599/71781531599.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6dc940c6-0bc5-488e-bf3f-b6e97419722d.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2230e3b2-3403-4de2-a14f-66403e976d8b.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e97e2d9a-11db-45b0-ba25-1b4743afdb0e.pdf) |
| Nov 2016 | [Concall - Nov 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=BAE7D38B_ADCA_4C42_A9FF_E647F5F2099C_163129.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fa73d93d-6b97-4e8b-ae0a-46a1a2c11159.pdf) |
| May 2016 | [Concall - May 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68F46EFF_EBFB_4F97_898D_E176BD299040_194327.pdf) |
| Jun 2017 | [Concall - Jun 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/6/b9fbf3a7-5d13-4828-a40e-c8cbd5a8df85.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bf7867ab-6486-4960-b4c7-6e8b67dcc1e3.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/034273fa-d834-4e20-9555-e6e4e18a6765.pdf) |
| Dec 2021 | [Concall - Dec 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/16cb36e7-fd5c-4206-b4c7-fd3d404b3671.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:59:35.587Z.